PHIO News and Press, Phio Pharmaceuticals Corp. From 04/17/23

Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity PR Newswire - Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 - MARLBOROUGH, Mass. , Apr...

2023-03-22 17:20:48 ET Phio Pharmaceuticals press release ( NASDAQ: PHIO ): FY GAAP EPS of -$10.10 beats by $0.82 . At December 31, 2022, the Company had cash of $11.8 million as compared with $24.1 million at December 31, 2021. The Company expects its current cash wil...

Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update PR Newswire – Following safety data review by the DMC, enrollment is now open for the second cohort of its Phase 1b study of PH-762 for the treatment of advanced melanoma ...

Phio Pharmaceuticals ( NASDAQ: PHIO ) has appointed Robert Bitterman as its president and chief executive officer, effective as of February 20, 2023. Bitterman has served as interim CEO of the biotech firm since Sep. 2022 and will continue to be the chair of its board, as well as ...

Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer PR Newswire MARLBOROUGH, Mass. , Feb. 22, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL!...

Phio Pharmaceuticals ( NASDAQ: PHIO ) has received a letter from The Nasdaq advising the Company that it has regained complianc e with Nasdaq's minimum bid price listing requirement. Phio has satisfied the terms by complying with the minimum bid price requirement of $1/share under...

Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements PR Newswire MARLBOROUGH, Mass. , Feb. 13, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platfo...

Phio Pharmaceuticals ( NASDAQ: PHIO ) said an independent Data Monitoring Committee (DMC) recommended proceeding to the enrollment of the next dose group after reviewing interim safety data from a phase 1b trial of PH-762 to treat advanced melanoma. After completing the treatment...

Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification PR Newswire MARLBOROUGH, Mass. , Feb. 10, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechn...

Phio Pharma ( NASDAQ: PHIO ) said it had approved a reverse stock split of its shares at a ratio of 1-for-12, which will be effective at 12:01 a.m. Eastern Time on Jan 26. ( PHIO ) is trading ~10% lower premarket. The reverse stock split is being done to increase ...